Interestingly, perturbation of ATM resulted in terminal differentiation of murine myeloid blasts expressing MLL-AF9 (26), providing rationale for the use of ATM inhibitors for treatment of MLL-rearranged AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.